drugset / Trial / NCT00740181
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
Phase 2
Terminated
9 enrolled
Brown University
Memorial Hospital of Rhode Island · collabRoger Williams Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will determine the activity of decitabine, low dose cytarabine (ARA-C) and G-CSF for patients with myelodysplasia and leukemia.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-02
- Completion
- 2010-04
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 20 mg/m2 | Subcutaneous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |